ACTIV-1 infliximab, 0 NCT04593940
infliximab (n=518) vs. placebo (n=519)
randomized controlled trial
risk of bias NA
infliximab
placebo
in addition to the standard of care, which may include remdesivir. About 90% received remdesivir, and about 85% received dexamethasone
COVID-19 severe or critically
preliminary results in a press release